Peter Arduini
President and CEO
Replay available
GE HealthCare Technologies Inc. (NASDAQ: GEHC) Q1 2025 earnings conference call, held 2025-04-30. Replay captured from the company's public earnings webcast.

President and CEO
Vice President and CFO
Wells Fargo (Analyst)
Piper Sandler (Analyst)
Evercore ISI (Analyst)
J.P. Morgan (Analyst)
Goldman Sachs (Analyst)
Citi (Analyst)
BofA Securities (Analyst)
Mizuho Financial Group (Analyst)
Good day, and thank you for standing by. Welcome to the GE Healthcare first quarter 2025 earnings conference call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Carolyn Borders. Please go ahead. Carolyn Borders Thanks, operator. Good morning and welcome to GE Healthcare's first quarter 2025 earnings call. I'm joined by our President and CEO, Peter Arduini, and Vice President and CFO, Jay Saccaro. Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website. During this call, we'll make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. With that, I'll hand the call over to Peter. Thanks, Carolyn. Good morning, and thank you for joining us. Our first quarter results reflect strong execution as we start the year, with revenue and profit growth that exceeded our expectations. Record double-digit orders growth as a standalone company was driven by strength in the U.S. market, where we see customers prioritizing investments in imaging products with a particular focus on cardiology and oncology. Early indications from market data...